XBiotech (XBIT) Other financing activities (2015 - 2024)

XBiotech (XBIT) posted quarterly Other financing activities of $33000.0 for Q4 2024, down 48.44% quarter-over-quarter from $64000.0 in Q3 2024.

XBiotech (XBIT) Other financing activities (2015 - 2024) Analysis & Trends

XBiotech's Other financing activities history runs 9 years deep, the most recent figure standing at $33000.0 for Q4 2024.

In Q4 2024, Other financing activities changed N/A year-over-year to $33000.0; the TTM figure through Sep 2025 stood at $33000.0 (down 80.24% YoY), while the FY2024 annual figure was $200000.0, up 3900.0% from the prior year.
Other financing activities for Q4 2024 stood at $33000.0, down from $64000.0 in the prior quarter.
The five-year high for Other financing activities was $7.9 million in Q1 2020, with the low at -$150000.0 in Q4 2020.
The 4-year median for Other financing activities is $64000.0 (2024), against an average of $1.4 million.
Peak annual rise in Other financing activities reached 3859.0% in 2020, while the deepest fall reached 105.78% in 2020.
XBiotech's Other financing activities stood at -$150000.0 in 2020, then surged by 122.0% to $33000.0 in 2021, then plunged by 84.85% to $5000.0 in 2023, then surged by 560.0% to $33000.0 in 2024.
Business Quant data shows XBIT's Other financing activities at $33000.0 in Q4 2024, $64000.0 in Q3 2024, and $48000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	XBiotech	68.90 Mn	68.90 Mn	-

Download Data